#London #United Kingdom #gene therapy #RNAi #CGT Innovation

Global Leaders to Discuss Innovations in Cell and Gene Therapy at 2025 London Forum

Upcoming Global Forum on Cell and Gene Therapy

On November 20, 2025, London will host a significant forum focusing on the rapid advancements in cell and gene therapies (CGT) that are revolutionizing modern medicine. This event, organized by GenScript Biotech Corporation in conjunction with the Jefferies London Healthcare Conference, promises to be a platform for dialogue among notable scientists, industry leaders, and investors under the theme, "THE NEXT ERA OF CGT IS HERE."

The health sector is on the verge of a major shift, fueled by innovations like CRISPR genome editing and various cell therapies. With significant investments and innovation pouring into the sector, CGT has emerged as one of the fastest-growing fields within life sciences. However, translating these scientific breakthroughs into lasting clinical benefits for patients poses a substantial challenge.

Renowned Speakers Illuminate the Future of CGT

Among the highlights of the forum will be keynote speeches from esteemed figures in the biomedical field. Dr. Craig Mello, honored with the Nobel Prize in Physiology or Medicine in 2006, will focus on the evolution of foundational science into real-world therapeutic applications. His work on RNA interference has set the stage for novel RNA-based treatments that are becoming standard in patient care today. Dr. Mello’s insights will be critical for understanding the lessons learned that can guide the next generation of CGT.

Dr. Carl June will also address the audience; he is a pioneer in immunotherapy and credited with developing the first FDA-approved CAR-T therapy. His experience will be instrumental in discussing the latest clinical breakthroughs in cellular immunotherapies and their implications for future cancer treatments.

Additionally, Dr. Miguel Forte, leader of the International Society for Cell and Gene Therapy, will share his regulatory expertise, offering insights on clinical translation and manufacturing challenges that await the industry as it seeks to become more scalable and accessible.

Expanding Horizons: Innovations in Cell Therapy

The forum will delve into the diversification of cell therapy strategies, including autologous and allogeneic processes. As these methods evolve, they pose unique challenges concerning scalability, safety, and cost-effectiveness. Panel discussions featuring industry leaders like Paula Río (CIEMAT), Marcello Maresca (AstraZeneca), and Paul Stoffels will explore how these various therapy types are adapting to meet patient care demands in real-time.

Moreover, Dr. Ying Huang, CEO of Legend Biotech, will recount the success story of his company, which has emerged as a leader in CAR-T therapies, offering valuable perspectives on commercializing groundbreaking technologies.

Gene Therapy: From Promise to Practice

Gene therapy and mRNA technologies are making remarkable strides, transitioning from theoretical research into practical applications that yield tangible clinical results. However, concerns persist regarding the durability of these therapies and their delivery mechanisms. Panels featuring experts such as Julen Oyarzabal (Syngoi Technologies) and Robin Shattock (Imperial College London) will address these issues while discussing the latest advancements and emerging trends.

Manufacturing Challenges: Ensuring Access for All

Despite the excitement surrounding CGT, the path from discovery to treatment is fraught with manufacturing hurdles that must be addressed to ensure broad patient access. Experts including Jin Yin (ProBio) and Dima Al-hadithi (Minaret Consulting) will share strategies to overcome these challenges. Their experiences in the field will highlight how innovation in manufacturing can lead to improved scalability and compliance with regulatory standards.

Investment and Innovation: Shaping CGT's Future

Investment interest in CGT has surged, yet converting scientific breakthroughs into sustainable business models necessitates a strong alignment between innovators and investors. Panelists like Michael Brinkman (Jefferies) and Laura Stoppel (RA Capital Management) will provide insights into how capital is being strategically invested to foster emerging CGT companies, emphasizing the crucial intersection of scientific advancement and financial strategy.

Register Now

For those interested in attending this groundbreaking forum, registration is now open, offering the first 20 registrants a complimentary ticket using the code GSGM2. Join leaders in London on November 20th for a chance to engage with cutting-edge discussions poised to shape the future of health care.